Searches , social queries for REACTOGENICITY
Search references for REACTOGENICITY. Phrases containing REACTOGENICITY
See searches and references containing REACTOGENICITY!
Search references for REACTOGENICITY. Phrases containing REACTOGENICITY
See searches and references containing REACTOGENICITY!REACTOGENICITY
Expected reaction to a vaccine
manifestations of reactogenicity typically identified in such trials include bruising, redness, induration, and swelling. The term reactogenicity was coined
Reactogenicity
Type of vaccine
that protect the RNA strands and help their absorption into the cells. Reactogenicity, the tendency of a vaccine to produce adverse reactions, is similar
MRNA_vaccine
Infection caused by Bacillus anthracis bacteria
currently used anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever) and serious adverse reactions
Anthrax
Vaccines against the bacterium Bacillus anthracis
currently used anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever) and serious adverse reactions
Anthrax_vaccine
Vaccine to prevent cholera
but were largely abandoned in the 1970s due to their then-documented reactogenicity and poor efficacy. Oral cholera vaccines were first introduced in the
Cholera_vaccine
Viral disease
Diseases (NIAID) (1 June 2018), A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without
Yellow_fever
Species of Gram-positive bacterium
Clinical trial number NCT01160172 for "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational
Staphylococcus_aureus
Vaccine candidate against COVID-19
Biotech Co., Ltd. It was found to be safe and well tolerated. "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy
LYB001
New Zealand vaccinologist
doctorate and wrote a thesis titled Factors associated with vaccine reactogenicity in school aged children and young adults following administration of
Helen_Petousis-Harris
Vaccine candidate against COVID-19
Rec-Biotechnology Co Ltd. Clinical trial number NCT04818801 for "Safety, Reactogenicity and Immunogenicity Study of ReCOV" at ClinicalTrials.gov Clinical trial
ReCOV
Clinical research to establish the characteristics of COVID-19 vaccines
20 October 2021. NCT05084989. Retrieved 20 October 2021. "Safety, Reactogenicity and Immunogenicity Study of ReCOV". ClinicalTrials.gov. 26 March 2021
COVID-19 vaccine clinical research
COVID-19_vaccine_clinical_research
Virus responsible for hemorrhagic fever
a single-injection vaccine has been shown to not cause any adverse reactogenicity, which is the possible immune response to vaccination, in comparison
Marburg_virus
Vaccine primarily used against tuberculosis
which owns the Brazilian substrain M. bovis BCG Moreau which is less reactogenic than vaccines including other BCG strains. Pacis BCG, made from the Montréal
BCG_vaccine
Hungarian-American biochemist (born 1955)
Jae-Hwan (July 2023). "Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines". Experimental & Molecular Medicine. 55 (7): 1305–1313
Katalin_Karikó
Vaccine against respiratory syncytial virus
gov Clinical trial number NCT04732871 for "Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV)
Respiratory syncytial virus vaccine
Respiratory_syncytial_virus_vaccine
original on 2 March 2022. Retrieved 2 March 2022. "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19
List of COVID-19 vaccine authorizations
List_of_COVID-19_vaccine_authorizations
RNA COVID-19 vaccine
number NCT04405076 for "Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18
Moderna_COVID-19_vaccine
Species of bacterium
pub3. PMC 6481520. PMID 28626902. "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational
Haemophilus_influenzae
Vaccine against COVID-19
in the ClinicalTrials.gov database. The trial "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19
EpiVacCorona
Viral vector vaccine for prevention of COVID-19
J, Hielscher F, Marx S, et al. (26 July 2021). "Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination". Nature Medicine.
Oxford–AstraZeneca COVID-19 vaccine
Oxford–AstraZeneca_COVID-19_vaccine
Reduction of disease among the vaccinated comparing to the unvaccinated
asymptomatic infection, serious adverse events due to vaccination, vaccine reactogenicity, and cost effectiveness of the vaccine. Vaccine efficacy is calculated
Vaccine_efficacy
Chronic and multi-symptomatic disorder
McNeil MM, Chiang IS, Wheeling JT, Zhang Y (March 2007). "Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study
Gulf_War_syndrome
Vaccine against COVID-19
Interim results from the phase I–IIa trial established the safety, reactogenicity, and immunogenicity of Ad26.COV2.S. With one dose, after 29 days, the
Janssen_COVID-19_vaccine
Pharmaceutical drug
attenuated live virus vaccine with optimal immune response and minimal reactogenicity have been unsuccessful. Further research on animal subjects suggested
Palivizumab
Vaccine candidate against COVID-19
31 May 2025. Retrieved 26 June 2025. "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults
MRNA-1283
Protein subunit vaccine against COVID-19
phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing
Corbevax
Ongoing COVID-19 vaccine program in Australia
January 2021. Retrieved 21 March 2021. "Phase 1 Study to Assess Safety, Reactogenicity and Immunogenicity of the HDT-301 Vaccine Against COVID-19". clinicaltrials
COVID-19 vaccination in Australia
COVID-19_vaccination_in_Australia
Vaccine against COVID-19
Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine
Covaxin
Vaccine candidate against COVID-19
Next Year". The Astana Times. Clinical trial number NCT04530357 for "Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine" at ClinicalTrials
QazCovid-in
American scientist, pediatrician, and advocate (born 1958)
ISSN 1873-2518. PMC 9549940. PMID 36114129. "A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for
Peter_Hotez
Vaccine against malaria
pre-erythrocytic phase. However, problems were encountered due to low efficacy, reactogenicity and low immunogenicity. [citation needed] The initial stage in the lifecycle
Malaria_vaccine
Vaccine that protects against yellow fever
Diseases (NIAID) (1 June 2018), A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without
Yellow_fever_vaccine
Surge of HMPV cases in 2024–2025 (China)
Retrieved 6 January 2025. Clinical trial number NCT03392389 for "Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults" at ClinicalTrials
HMPV seasonal outbreak in China (2024)
HMPV_seasonal_outbreak_in_China_(2024)
Species of virus
PMID 17458775. S2CID 21308968. Clinical trial number NCT03392389 for "Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults" at ClinicalTrials
Human_metapneumovirus
Plan to immunize against COVID-19 in South Africa
March 2021). "An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants"
COVID-19 vaccination in South Africa
COVID-19_vaccination_in_South_Africa
COVID-19 vaccine candidate
series, resulted in an increased immune response without increase in reactogenicity. Linnane C (8 March 2020). "Inovio shares rally after biotech says human
Inovio_COVID-19_vaccine
Vaccine candidate against COVID-19
Questex LLC. Retrieved 5 January 2021. "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". clinicaltrials
CureVac_COVID-19_vaccine
American biotech firm
Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult
Arcturus_Therapeutics
Component of vaccines
water-in-oil emulsion, a classical adjuvant. Water-in-oils are generally too reactogenic to be used on humans, however. Squalene is a natural oil made by human
Immunologic_adjuvant
Vaccine in development
ClinicalTrials.gov". 21 June 2021. "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers". Retrieved
Zika_virus_vaccine
COVID-19 vaccination programme in Canada
12, 2021). "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data". The Lancet. 397 (10289): 2043–2046. doi:10.1016/S0140-6736(21)01115-6
COVID-19 vaccination in Canada
COVID-19_vaccination_in_Canada
Ongoing COVID-19 vaccine programme in New Zealand
the original on 6 January 2024. Retrieved 6 January 2024. "Safety, Reactogenicity and Immunogenicity Study of ReCOV". clinicaltrials.gov. United States
COVID-19 vaccination in New Zealand
COVID-19_vaccination_in_New_Zealand
Vaccine against COVID-19
Trials, with an open, sequential and adaptive study to assess safety, reactogenicity and explore immunogenicity of the vaccine. Phase IIa involved 100 Cubans
Soberana_02
Vaccine candidate against COVID-19
in 2022. In June 2020, Phase I trial were launched to assess safety, reactogenicity, and immunogenicity at multiple dose levels with 151 participants in
SCB-2019
Universal coronavirus vaccine candidate
NCT07280858 for "A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511)
GBP511
Italian-American virologist
Dhitavat J, Maekanantawat W, Pungpak S, et al. (2011). "Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination
Enzo_Paoletti
Clinical trials of influenza vaccine
adults, 18 to 49 years old, is designed to investigate the safety, reactogenicity, and dose-related immunogenicity of an investigational inactivated influenza
H5N1_vaccine_clinical_trials
Clinical trial of an HIV vaccine in Thailand
M. L.; Kim, J. H. (2011). Kallas, Esper Georges (ed.). "Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination
RV_144
Israeli researcher
degradability of the lipids using special rational design; and the lipid reactogenicity. These lipids have been licensed to several major pharmaceutical companies
Dan_Peer
Plan to immunize against COVID-19
Retrieved 8 July 2021. "A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19". ClinicalTrials.gov
COVID-19 vaccination in Thailand
COVID-19_vaccination_in_Thailand
Vaccine adjuvant
(mainly QS-21). Matrix-C has strong adjuvant activity but is also highly reactogenic (lethargy and lethality in mice). The remaining 85% are known as Matrix-A
Matrix-M
Vaccine against Marburg virus disease
Using a single-injection vaccine has shown to not cause any adverse reactogenicity, which the possible immune response to vaccination, in comparison to
Marburg_vaccine
American bioethicist and academic (born 1956)
Jureidini, British Medical Journal (BMJ), 376, 2022, pp. 702–03. "A Reactogenic 'Placebo' and the Ethics of Informed Consent in the Gardasil HPV Vaccine
Leemon_McHenry
Soviet microbiologist, virologist (1901-1986)
Ilyenko, V. I., Gorev, N. E. et al. (1959). Results of a study of the reactogenic and immunogenic properties of live anti-poliomyelitis vaccine. Bulletin
Anatolii_Smorodintsev
American physician and immunologist
ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity". PLOS ONE. 5 (8) e11995. Bibcode:2010PLoSO...511995G. doi:10.1371/journal
Barton_Haynes
Dutch microbiologist and bacterial vaccine expert
Begg, N.; Richmond, P.; Poolman, J. (1999-06-04). "Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple
Jan_Poolman
travel, tourism, insurance
REACTOGENICITY
REACTOGENICITY
REACTOGENICITY
REACTOGENICITY
REACTOGENICITY
REACTOGENICITY
REACTOGENICITY
REACTOGENICITY
REACTOGENICITY
travel, tourism, insurance